A variety of intricate cancer therapies known as antibody-drug conjugates (ADCs) have undergone clinical testing and been approved for use on patients. To explain the possible risks associated with these medications, researchers have conducted an extensive analysis of different scientific databases.
A variety of intricate cancer therapies known as antibody-drug conjugates (ADCs) have undergone clinical testing and been approved for use on patients. To explain the possible risks associated with these medications, researchers have conducted an extensive analysis of different scientific databases.
ADCs, or antibody drug conjugates, are a class of complicated cancer treatments that have undergone extensive testing in clinical studies. The study explained the potential hazards related to these drugs.
\
\
\
\
